心智观察所：独家对话|周露：生物医药出海，超过了新能源车

Core Insights - Gene therapy is rapidly transforming the landscape of disease treatment, with a focus on unlocking its broader, more precise, and accessible potential [1] - The integration of artificial intelligence (AI) with biomedicine is seen as a key variable for the future of gene therapy [1] Company Background - The co-founder of Shentuo Biotechnology, Zhou Lu, transitioned from academia to entrepreneurship, previously establishing a business development service in the UK that assisted over 30 listed companies [3][4] - The COVID-19 pandemic prompted a shift in focus towards innovative drug development, leading to the establishment of Shentuo Biotechnology in 2023 [5][6] Market Dynamics - The capital market showed significant interest in innovative therapies during the early stages of the COVID-19 pandemic, but enthusiasm waned by late 2022, leading to a "capital winter" [6][7] - In the first half of 2023, there was a resurgence in capital investment in biomedicine, with the total overseas transaction amount for biopharmaceuticals reaching nearly $50 billion, surpassing the total sales of electric vehicles [7][8] Technological Innovation - Shentuo Biotechnology is focused on developing a fifth-generation lentiviral vector platform, which aims to enhance safety and efficacy through iterative improvements [8][9] - The new platform allows for in vivo modification of cells, potentially reducing costs and increasing accessibility for patients [10][11] Treatment Paradigm Shift - The company's approach emphasizes enhancing the natural protective capabilities of cells, specifically targeting tumor suppressor genes rather than merely attacking cancer cells [12][13] - This method is likened to "reprogramming" cells, allowing for the potential transformation of cancer cells back into normal cells [14][15]